Literature DB >> 16161041

Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor.

Ioannis Panagopoulos1, Therese Nilsson, Henryk A Domanski, Margareth Isaksson, Pia Lindblom, Fredrik Mertens, Nils Mandahl.   

Abstract

Inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic spindle cells and infiltrating inflammatory cells. Cytogenetic analyses have revealed that a subgroup of IMT, in particular among children and young adults, harbors clonal chromosomal rearrangements involving chromosome band 2p23. Further, molecular genetic studies have shown that these rearrangements target the ALK gene, serving as the 3'-partner in fusion genes with various translocation partners. In the present study, we describe the finding of a novel SEC31L1/ALK fusion gene in an intraabdominal IMT of a young man. G-band analysis revealed a translocation t(2;4)(p23;q21) and subsequent fluorescence in situ hybridization with locus-specific probes strongly indicated disruption of the ALK locus on chromosome 2. Immunostaining with monoclonal mouse anti-human CD246 ALK Protein showed diffuse cytoplasmic positivity. Using reverse primers for the ALK-gene, we could, by 5'-RACE methodology, amplify a single 1.2 kb fragment. Sequence analysis showed that the fragment was a hybrid cDNA product in which nt 3012 of SEC31L1 (NM_016211), located in band 4q21, was fused in-frame to nt 4080 of ALK (NM_004304). RT-PCR with two sets of primer pairs specific for SEC31L1 and ALK amplified two transcripts, which at sequencing corresponded to two types of chimeric SEC31L1/ALK transcripts. In the long, type I, transcript nt 3012 of SEC31L1 (NM_016211) was fused in-frame to nt 4080 of ALK. In the short, type II, transcript nt 2670 of SEC31L1 was fused in-frame to nt 4080 of ALK. Genomic PCR and subsequent sequencing showed that the breakpoints were located in intron 23 of SEC31L1 and intron 20 of ALK. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16161041     DOI: 10.1002/ijc.21490

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.

Authors:  Clare Bedwell; David Rowe; Deborah Moulton; Gail Jones; Nick Bown; Chris M Bacon
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Authors:  Fernando Vargas-Madueno; Edwin Gould; Raul Valor; Nhu Ngo; Linsheng Zhang; Miguel A Villalona-Calero
Journal:  Oncologist       Date:  2018-05-08

3.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 4.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

5.  Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.

Authors:  Jennifer A Bennett; Valentina Nardi; Marjan Rouzbahman; Vicente Morales-Oyarvide; G Petur Nielsen; Esther Oliva
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 6.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 7.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

8.  Omental mesenteric myxoid hamartoma, a subtype of inflammatory myofibroblastic tumor? Considerations based on the histopathological evaluation of four cases.

Authors:  K Ludwig; R Alaggio; P Dall'Igna; E Lazzari; E S G d'Amore; P M Chou
Journal:  Virchows Arch       Date:  2015-09-19       Impact factor: 4.064

Review 9.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.